Fate Therapeutics Announces Abstract Highlighting FT538 and FT573 Programs Selected for Presentation at SITC 2021 Annual Meeting Press Conference
09 nov. 2021 09h00 HE
|
Fate Therapeutics, Inc.
Company to Host Virtual Investor Event on Monday, November 15 SAN DIEGO, Nov. 09, 2021 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company...
Fate Therapeutics Reports Third Quarter 2021 Financial Results and Highlights Operational Progress
04 nov. 2021 16h01 HE
|
Fate Therapeutics, Inc.
Initiated Enrollment in Phase 1 Clinical Studies of FT538 and FT576 for R/R Multiple Myeloma FT596 Interim Phase 1 Data of 14 Patients in Single-Dose Escalation Cohorts 2 and 3 for R/R Lymphoma...
Fate Therapeutics Announces Eight Presentations at the 2021 ASH Annual Meeting
04 nov. 2021 09h01 HE
|
Fate Therapeutics, Inc.
FT596 Oral and FT516 Poster Presentations to Highlight Updated Clinical Data for Relapsed / Refractory Lymphoma on Monday, December 13 Company to Host Virtual Investor Event on Tuesday, December 14 ...
Fate Therapeutics to Webcast Conference Call Reporting Third Quarter 2021 Financial Results
25 oct. 2021 08h00 HE
|
Fate Therapeutics, Inc.
SAN DIEGO, Oct. 25, 2021 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (the “Company” or “Fate Therapeutics”) (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to the development of...
Fate Therapeutics Announces Presentations at the Society for Immunotherapy of Cancer 2021 Annual Meeting
01 oct. 2021 08h01 HE
|
Fate Therapeutics, Inc.
SAN DIEGO, Oct. 01, 2021 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies...
Fate Therapeutics Announces Publication of FT538 Preclinical Data Demonstrating Enhanced Serial Killing and Functional Persistence without Cytokine Support
15 sept. 2021 08h00 HE
|
Fate Therapeutics, Inc.
SAN DIEGO, Sept. 15, 2021 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies...
Fate Therapeutics to Present at Upcoming Investor Conferences
02 sept. 2021 16h01 HE
|
Fate Therapeutics, Inc.
SAN DIEGO, Sept. 02, 2021 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies...
Fate Therapeutics Announces Positive Interim Clinical Data from its FT596 and FT516 Off-the-shelf, iPSC-derived NK Cell Programs for B-cell Lymphoma
19 août 2021 16h01 HE
|
Fate Therapeutics, Inc.
10 of 14 Patients in FT596 Single-Dose Escalation Cohorts 2 and 3 Achieved Objective Response; 7 Patients Achieved Complete Response, including 2 of 3 Patients Treated with FT596 in Combination with...
Fate Therapeutics Reports Second Quarter 2021 Financial Results and Highlights Operational Progress
04 août 2021 16h01 HE
|
Fate Therapeutics, Inc.
First Patient Treated for Relapsed / Refractory ALL in Landmark Phase 1 Clinical Trial of FT819, the First-ever iPSC-derived CAR T-cell Therapy; Off-the-Shelf Product Candidate Derived from Clonal...
Fate Therapeutics Appoints Yuan Xu to its Board of Directors
04 août 2021 08h00 HE
|
Fate Therapeutics, Inc.
SAN DIEGO, Aug. 04, 2021 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies...